Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30196% above fair value
$11.62+0.72 (+6.61%)
Close on Nov 13, 2026Market cap $407.48MP/E 387.3Yield –
Fennec Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Fennec Pharmaceuticals's EV/EBITDA was 54.4× on Apr 30, 2025.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Apr 30, 2025 | 54.4× | −24.6 |
| 2024 | Dec 31, 2024 | 79.0× | – |
See a number that looks wrong?